Smithkline Beecham Corporation

Jeremy David Hinks

Eric Hunt

Steven Coulton

George Burton

Andrew Kenneth Takle

Stephen Frederick Moss

Stephen Christopher Martin Fell

Alfred John Eglington

A compound of formula (I):whereinRis hydrogen, optionally substituted (C)alkyl or optionally substituted aryl;Ris hydrogen, optionally substituted (C)alkyl or optionally substituted aryl; orRand Rtogether form an optionally substituted 5 or 6 membered heterocyclic ring with or without additional heteroatoms;Ris (C)alkyl which is unsubstituted or substituted by fluoro, a hydroxy group which is optionally protected by a removable hydroxy protecting group, or by an amino group which is optionally protected by a removable amino protecting group;Ris hydrogen or methyl; and&#x2014;CORis carboxy or a carboxylate anion or the group Ris a removable carboxy protecting group. This invention also relates to processes for its preparation, intermediates and pharmaceutical compositions comprising compounds of formula (I). Compounds of formula (I) which include pharmaceutically acceptable salts or pharmaceutically acceptable in vivo hydrolysable esters thereof have a broad spectrum of anti-bacterial activity and show good stability towards DHP-1.

2-(pyrazol-3-yl)carbapenem derivatives

Derivatives of mutiline of formula (1A) and pharmaceutically acceptable salts and derivatives thereof, in which R,is ethyl or vinyl, Y is a carbamoyloxy group, in which the N-atom is unsubstituted, or mono- or di-substituted, are useful in the treatment of bacterial infections.

Carbamoyloxy derivatives of mutiline and their use as antibacterials

Disclosed are a carbapenem compound represented by formula (I) and processes to its preparation.

Disclosed are 1-, 6- and 2-substituted-1-carba-2-penem-3-carboxylic acids, a process for their preparation, pharmaceutical compositions comprising said compounds and a method of using them to treat bacterial infections.

Growing community of inventors

Ashurst, United Kingdom

Jeremy David Hinks